石杉碱甲治疗轻中度阿尔茨海默病的临床研究

摘要

Objective To evaluate the clinical effect and safety of huperzine A on the patients with mild and moderate Alzheimer disease( AD ). Methods 60 patients with mild and moderate AD were randomly divided into treatment group( n =30 )and control group( n =30 ),treatment group was treated with huperzine A( 0. 2 mg,twice daily )and control group was treated with placebo for 12 weeks. Memory Quotient( MQ ), Mini-mental state examination ( MMSE ),HDS-R and ADL were measured respectively before treatment and after 12 weeks treatment. Results After 12 weeks treatment,MQ and MMSE in treatment group were obviously higher( P < 0. 01 ), and they were obviously higher than that in control group( P <0. 01 );ADL was obviously lower( P <0. 01 ),and it was also lower than that of control group( P <0. 01 ). Conclusion Huperzine A is safe and effective in the treatment for the patients with mild andrnmoderate AD.%目的 评价石杉碱甲治疗阿尔茨海默病(Alzheimer′s disease,AD)的临床疗效和安全性.方法 将60例轻、中度AD患者随机分为石杉碱甲组(治疗组)和安慰剂组(对照组),各30例.治疗组给予石杉碱甲片0.2 mg,2次/d口服;对照组口服安慰剂,2次/d口服.疗程均为12周.治疗前后分别测定记忆商(Memory Quotient,MQ)、简易智力状态检查(Mini-mental state examination,MMSE)、长谷川痴呆修正量表(HDS-R)、工具性日常生活活动能力量表(ADL)的变化.结果 治疗12周后,治疗组AD患者MQ、MMSE积分显著提高(P<0.01),与对照组治疗后比较,差异有统计学意义(P<0.01);ADL积分降低,与治疗前比较,差异有统计学意义(P<0.01),与对照组治疗后比较,差异有统计学意义(P<0.01).结论 石杉碱甲片对轻、中度AD有较好疗效,且副作用较少,是安全性较好的药物.